enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada. Show more
Location: 4868 Rue Levy, Montreal, QC, H4R 2P1, Canada | Website: https://www.engene.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
478.6M
52 Wk Range
$2.65 - $10.06
Previous Close
$9.33
Open
$9.02
Volume
48,358
Day Range
$9.02 - $9.40
Enterprise Value
246.2M
Cash
201.9M
Avg Qtr Burn
-23.46M
Insider Ownership
13.60%
Institutional Own.
89.60%
Qtr Updated
07/31/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Detalimogene (EG-70) Details Non-Muscle Invasive Bladder Cancer (NMIBC) | Phase 2 Data readout |